General description
Dactinomycin is an antineoplastic agent that inhibits DNA, RNA and protein synthesis. It is used in treatment protocols for many cancers including gestational trophoblastic neoplasia, rhabdomyosarcoma and Wilms tumour (nephroblastoma).
INN
Dactinomycin
ATC codes
Medicine type
Chemical agent
EML status history
First added in 1984
(TRS
722)
for
Malignant trophoblastic neoplasms of placenta
Added in 1984
(TRS
722)
for
Malignant neoplasms of kidney, except renal pelvis
Added in 1984
(TRS
722)
for
Rhabdomyosarcoma primary site
Added in 1984
(TRS
722)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Removed in 2015
(TRS
994)
for
Unspecified malignant neoplasms of ill-defined or unspecified sites
Added in 2021
(TRS
1035)
for
Ewing sarcoma of bone and articular cartilage of unspecified sites
Wikipedia
DrugBank
Recommendations
Section
Cytotoxic medicines
- Parenteral > General injections > IV: 500 µg in vial powder for injection